487 related articles for article (PubMed ID: 8772549)
1. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
[TBL] [Abstract][Full Text] [Related]
2. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
[TBL] [Abstract][Full Text] [Related]
3. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
[TBL] [Abstract][Full Text] [Related]
4. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
[TBL] [Abstract][Full Text] [Related]
5. Acute pharmacological reduction of plasma free fatty acids enhances the growth hormone (GH)-releasing hormone-mediated GH secretion in patients with Cushing's syndrome.
Leal-Cerro A; Jimenez LM; Astorga R; Fernandez-Lopez I; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1997 Sep; 82(9):3165-8. PubMed ID: 9284763
[TBL] [Abstract][Full Text] [Related]
6. Effect of acute reduction of free fatty acids by acipimox on growth hormone-releasing hormone-induced GH secretion in type 1 diabetic patients.
Alvarez P; Isidro L; Peinó R; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F
Clin Endocrinol (Oxf); 2003 Oct; 59(4):431-6. PubMed ID: 14510904
[TBL] [Abstract][Full Text] [Related]
7. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
[TBL] [Abstract][Full Text] [Related]
8. Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men.
Van Dam PS; Smid HE; de Vries WR; Niesink M; Bolscher E; Waasdorp EJ; Dieguez C; Casanueva FF; Koppeschaar HP
J Clin Endocrinol Metab; 2000 Dec; 85(12):4706-11. PubMed ID: 11134132
[TBL] [Abstract][Full Text] [Related]
9. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
Peñalva A; Carballo A; Pombo M; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
[TBL] [Abstract][Full Text] [Related]
10. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.
Cordido F; Peñalva A; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1993 Apr; 76(4):819-23. PubMed ID: 8473389
[TBL] [Abstract][Full Text] [Related]
11. Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.
Nam SY; Lee ; Kim KR; Lee HC; Nam MS; Cho JH; Huh KB
Metabolism; 1996 May; 45(5):594-7. PubMed ID: 8622602
[TBL] [Abstract][Full Text] [Related]
12. Acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid levels in hyperthyroidism.
Lee EJ; Kim KR; Lee HC; Cho JH; Nam MS; Nam SY; Song YD; Lim SK; Huh KB
Metabolism; 1995 Nov; 44(11):1509-12. PubMed ID: 7476342
[TBL] [Abstract][Full Text] [Related]
13. Effect of acipimox, a lipid lowering drug, on growth hormone (GH) response to GH-releasing hormone in normal subjects.
Pontiroli AE; Lanzi R; Monti LD; Pozza G
J Endocrinol Invest; 1990 Jun; 13(6):539-42. PubMed ID: 2258583
[TBL] [Abstract][Full Text] [Related]
14. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level.
Popovic V; Damjanovic S; Micic D; Djurovic M; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1995 Mar; 80(3):942-7. PubMed ID: 7883854
[TBL] [Abstract][Full Text] [Related]
15. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection.
Pombo M; Barreiro J; Peñalva A; Peino R; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1995 Nov; 80(11):3180-4. PubMed ID: 7593423
[TBL] [Abstract][Full Text] [Related]
16. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
[TBL] [Abstract][Full Text] [Related]
17. Evidence for an inhibitory effect of physiological levels of insulin on the growth hormone (GH) response to GH-releasing hormone in healthy subjects.
Lanzi R; Manzoni MF; Andreotti AC; Malighetti ME; Bianchi E; Sereni LP; Caumo A; Luzi L; Pontiroli AE
J Clin Endocrinol Metab; 1997 Jul; 82(7):2239-43. PubMed ID: 9215300
[TBL] [Abstract][Full Text] [Related]
18. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
Cordido F; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
[TBL] [Abstract][Full Text] [Related]
19. Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.
Cordido F; Alvarez-Castro P; Isidro ML; Casanueva FF; Dieguez C
Eur J Endocrinol; 2003 Aug; 149(2):117-22. PubMed ID: 12887288
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6.
Popovic V; Damjanovic S; Micic D; Petakov M; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1994 Aug; 79(2):456-60. PubMed ID: 8045963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
